PMID- 33607862
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 7
DP  - 2021 Feb 19
TI  - The efficacy and safety of glucokinase activators for the treatment of type-2 
      diabetes mellitus: A protocol for systematic review and meta-analysis.
PG  - e24873
LID - 10.1097/MD.0000000000024873 [doi]
LID - e24873
AB  - BACKGROUND: Glucokinase activators are a novel family of glucose-lowering agents 
      used for the treatment of type-2 diabetes mellitus (T2DM). Glucokinase activators 
      blind to GK activate the enzyme allosterically. Treatment with different GKAs has 
      been shown to reduce fasting and postprandial glucose in patients with type 2 
      diabetes. We compared the efficacy/safety of glucokinase activators in T2DM 
      patients through a meta-analysis. METHODS: We searched PubMed, Excerpt Medica 
      Database, and Cochrane Central Register of Controlled Trials databases for 
      articles published before December 30, 2020. Two independent reviewers extracted 
      the information from article. The quality of articles were assessed by 2 
      independent reviewers using the 5 items of scale proposed by Jadad. We computed 
      the weighted mean difference and 95% confidence interval (CI) for a change from 
      baseline to the study endpoint for glucokinase activators vs placebo. Egger test 
      and Begg test were used to assess the possible publication bias caused by the 
      tendency of published studies to be positive. RESULTS: The present meta-analysis 
      will compare the efficacy and safety of glucokinase activators and placebo for 
      the treatment of T2DM. CONCLUSIONS: This meta-analysis will provide advanced 
      evidence on the efficacy and safety of glucokinase activators for the treatment 
      of T2DM. ETHICS AND DISSEMINATION: Ethical approval and patient consent are not 
      required because this study is a literature-based study. This systematic review 
      and meta-analysis will be published in a peer-reviewed journal. PROSPERO 
      REGISTRATION NUMBER: CRD42021220364.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Gao, Qian
AU  - Gao Q
AD  - Affiliated Hospital of Shaoxing University of Edocrine and Metabolism Department, 
      Zhejiang, China.
FAU - Zhang, Wenjun
AU  - Zhang W
FAU - Li, Tingting
AU  - Li T
FAU - Yang, Guojun
AU  - Yang G
FAU - Zhu, Wei
AU  - Zhu W
FAU - Chen, Naijun
AU  - Chen N
FAU - Jin, Huawei
AU  - Jin H
LA  - eng
GR  - grant NO.2018KY838/Medical and health projects in Zhejiang Province/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Enzyme Activators)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Placebos)
RN  - EC 2.7.1.2 (Glucokinase)
SB  - IM
MH  - Blood Glucose/analysis/drug effects
MH  - Case-Control Studies
MH  - Data Management
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Enzyme Activators/*pharmacology/therapeutic use
MH  - Fasting/blood
MH  - Glucokinase/*drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Placebos/administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Safety
MH  - Treatment Outcome
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7899907
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2021/02/21 06:00
MHDA- 2021/03/02 06:00
PMCR- 2021/02/19
CRDT- 2021/02/20 01:01
PHST- 2021/01/29 00:00 [received]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/02/20 01:01 [entrez]
PHST- 2021/02/21 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2021/02/19 00:00 [pmc-release]
AID - 00005792-202102190-00101 [pii]
AID - MD-D-21-00414 [pii]
AID - 10.1097/MD.0000000000024873 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Feb 19;100(7):e24873. doi: 
      10.1097/MD.0000000000024873.